Concepedia

PharmGKB summary

Daniella Lowenberg, Caroline F. Thorn, Zeruesenay Desta, David A. Flockhart, Russ B. Altman, Teri E. Klein

Pharmacogenetics and Genomics · 2013 · 25 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

Lowenberg, Daniella; Thorn, Caroline F.; Desta, Zeruesenay; Flockhart, David A.; Altman, Russ B.; Klein, Teri E. Author Information

References

15

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Corine Ekhart, Valerie D. Doodeman, Sjoerd Rodenhuis et al. · Pharmacogenetics and Genomics · 2008 · 133 citations

Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity

Katarina Aleksa, Douglas G. Matsell, Kris Krausz et al. · Pediatric Nephrology · 2005 · 80 citations

, , +8

Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC–ESI-QTOFMS-based metabolomics

Fei Li, Andrew D. Patterson, Constance C. Höfer et al. · Biochemical Pharmacology · 2010 · 64 citations · Full text

, , +11

Glutathione Conjugation of the Cytostatic Drug Ifosfamide and the Role of Human Glutathione S-Transferases

Hubert Dirven, Luc Megens, Martin J. Oudshoorn et al. · Chemical Research in Toxicology · 1995 · 58 citations

CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION

Jeannine S. McCune, Linda J. Risler, Brian Phillips et al. · Drug Metabolism and Disposition · 2005 · 52 citations